Product Overview
Composition
One tablet contains: Active substance: Prostate extract - 100 mg (in terms of water-soluble peptides - 20 mg); Excipients: Sucrose - 28.500 mg, Lactose monohydrate - 7.125 mg, Calcium stearate monohydrate - 2.500 mg, Crospovidone - 9.275 mg, Microcrystalline cellulose - up to 102.600 mg; Shell composition:
Acrylic-from (methacrylic acid and ethyl acrylate copolymer [1: 1],
titanium dioxide
talc,
triethyl citrate
silica colloidal
sodium bicarbonate,
sodium lauryl sulfate,
indigo carmine) - 25 mg.
pharmachologic effect
Vitaprost® has an organotropic effect on the prostate gland.
Reduces the degree of edema, leukocyte infiltration of the prostate gland, normalizes the secretory function of epithelial cells, increases the number of lecithin grains in the secret of acini, stimulates the muscle tone of the bladder.
It improves microcirculation in the prostate by reducing thrombosis, antiplatelet activity, and prevents the development of venous thrombosis in the prostate gland.
Based on clinical studies, Vitaprost® has been shown to moderately reduce prostate volume.
The drug reduces the severity of obstructive and irritative symptoms with benign prostatic hyperplasia, which is reflected in an increase in the maximum and average volumetric flow rates of urine and a decrease in the volume of residual urine.
Clinical studies have shown that the use of Vitaprost® reduces the likelihood of developing exacerbations of chronic abacterial prostatitis, does not cause changes in clinical and biochemical blood counts, or general urinalysis.
The effectiveness of the use of the drug Vitaprost® for the prevention of exacerbations of chronic abacterial prostatitis is estimated by researchers as 97.5%.
Vitaprost® normalizes the secretion parameters of the prostate gland and ejaculate. Reduces pain and discomfort caused by prostatitis, eliminates dysuric phenomena, improves copulative function.
Indications
- Chronic abacterial prostatitis.
- Prevention of exacerbations of chronic abacterial prostatitis.
- Benign prostatic hyperplasia.
- Conditions before and after surgical interventions on the prostate gland.
Contraindications
Hypersensitivity to the components of the drug.
Lactase deficiency, sucrose / isomaltase deficiency, lactose intolerance, fructose intolerance, glucose-galactose malabsorption (the drug contains lactose and sucrose).
Side effects
Very rarely - allergic reactions.
If any of the above side effects get worse or you notice any other side effects not listed in the instructions, notify your doctor.
Interaction
If you are taking any other medications, you should consult your doctor before starting treatment.
Cases of interaction or incompatibility with other drugs are not described.
How to take, course of administration and dosage
Inside, 1 tablet 2 times a day.
The duration of treatment with Vitaprost® for benign prostatic hyperplasia is at least 30 days, for chronic prostatitis - at least 10 days.
For the prevention of exacerbations of chronic prostatitis, 1 tablet is used 2 times a day for at least 30 days - 1-2 times a year.
The duration of treatment with Vitaprost® for benign prostatic hyperplasia is at least 30 days, for chronic prostatitis - at least 10 days.
For the prevention of exacerbations of chronic prostatitis, 1 tablet is used 2 times a day for at least 30 days - 1-2 times a year.
Overdose
No cases of drug overdose have been reported.
Special instructions
Treatment of chronic prostatitis and conditions before and after surgical interventions on the prostate gland should be comprehensive, suggesting, along with the appointment of Vitaprost® tablets, the use of other groups of drugs and non-drug methods of treatment.
Impact on the ability to drive vehicles and work with mechanisms
Does not affect the ability to drive a car and other mechanisms.
Release form
Enteric Coated Tablets
Storage conditions
At a temperature of no higher than 25 ° C.
Keep out of the reach of children.
Shelf life
3 years.
